# Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
Canonical URL: https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bank-of-america-health-care-conference-2026
Ticker: NBIX
Company: Neurocrine Biosciences
Source: Neurocrine Biosciences
Published: 2026-05-05 13:00 EST
Original Source URL: https://neurocrine.gcs-web.com
## Summary

SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20 a.m. Pacific Time (2:20 p.m Eastern Time) on May 12, 2026 in Las Vegas.

## Article Body
SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20 a.m. Pacific Time (2:20 p.m Eastern Time) on May 12, 2026 in Las Vegas.
## Recent Company News
- 2026-06-03 12:30 EST — [Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-new-two-year-crenessityr-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026) — Source: Neurocrine Biosciences
- 2026-05-26 20:01 EST — [Neurocrine Biosciences to Present at Upcoming Investor Conferences in June](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-june) — Source: Neurocrine Biosciences
- 2026-05-18 20:05 EST — [Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-real-world-data-highlighting-functional-impact-of-mild-tardive-dyskinesia-severity-and-improvement-with-ingrezzar-valbenazine-capsules) — Source: Neurocrine Biosciences
- 2026-05-18 12:46 EST — [Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-completes-acquisition-of-soleno-therapeutics) — Source: Neurocrine Biosciences
- 2026-05-06 12:30 EST — [Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-publication-of-expert-recommendations-for-glucocorticoid-dose-reduction-after-initiating-crenessityr-crinecerfont-for-the-treatment-of-classic-congenital-adrenal-hyperplasia) — Source: Neurocrine Biosciences
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)